TY - JOUR T1 - IL-17 and Th17-cells as markers of disease progression in pediatric allergic diseases. A therapeutic approach in an “<em>in vitro</em>” models JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p1832 AU - Mirella Profita AU - Loredana Riccobono AU - Rosalia Gagliardo AU - Caterina DiSano AU - Angela Marina Montalbano AU - Giusy Daniela Albano AU - Annalisa Ferlisi AU - Anna Bonanno AU - Pascal Chanez AU - Mark Gjomarkaj AU - Stefania La Grutta Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p1832.abstract N2 - Th17 cells and IL-17 play a role in allergy development and progression. We tested IL-17 in plasma (P), nasal wash (NW) and induced sputum (IS) from 12 healthy (HC), 14 intermittent asthma (IA) and 28 mild-moderate asthma (MA) with concomitant intermittent-rhinitis (IR, n=12) or concomitant persistent-rhinitis (PR, n=16); 2) intracellular CD3+IL-17+, CD3+RORgγt+ in peripheral blood (PB) T-cells from IA and MA children. In vitro we tested the effect of Budesonide (10-8M) and Formoterol (10-8M) alone or in combination on 1) intracellular CD3+IL-17+, CD3+RORγt+ expression in PBT-cells from children with MA and PR (n=10); 2) on the IL-8 release from nasal and bronchial epithelial cell lines pretreated with and without an anti-IL-17 receptor antibody and stimulated respectively with NW and IS from children with MA and PR (n=6). We observed significantly increased levels of 1) IL-17 in P, NW and IS from children with MA compared with IA and HC; 2) intracellular CD3+IL-17+ and CD3+RORγt+ in PBT-cells from subjects with MA compared with IA as well as in children with MA and PR when compared with MA and IR. In vitro experiments showed that Budesonide with Formoterol treatment significantly reduced 1) CD3+IL-17+ and CD3+RORγt+ in PBT-cells from children with MA and PR; 2) the effect of IL-17 present in NW and IS from children with MA and PR on IL-8 release in nasal and bronchial epithelial cell lines.IL-17 and Th17-cells are markers of disease progression in children with allergic MA and concomitant PR. Budesonide with Formoterol might be useful for a therapeutic approach to control IL-17 mediated allergic disorders.Funded by: Italchimici, S.p.A., Italia ER -